ReviewJournal of gastrointestinal oncology2017
Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma.
Review in Journal of gastrointestinal oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Radioprotectant-loaded visualizable cationic radioactive microspheres: Reduced hepatic tissue damage and intra/postoperative imaging during TARE.Materials today. Bio · 2026Article
- Hot Topics in the Surgical Treatment of Intrahepatic Cholangiocarcinoma: A Narrative Review of Current Managements.Cancers · 2025Review
- Contrast-enhanced CT as a non-invasive alternative for lung shunt fraction estimation in hepatic transarterial radioembolization.Radiology advances · 2025Article
- Y-90 PET/MR imaging optimization with a Bayesian penalized likelihood reconstruction algorithm.Physical and engineering sciences in medicine · 2024Article
- Translating contrast enhanced computed tomography images to liver radioembolization dose distribution for more comprehensively indicating patients.Physics in medicine and biology · 2024Article
- Applications of Yttrium-90 (OncoTargets and therapy · 2024Review
- Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.European journal of radiology open · 2023Article
- Liver transplantation for malignant liver tumors.iLIVER · 2022Review
- Selective Internal Radiation Therapy for Hepatocellular Carcinoma Across the Barcelona Clinic Liver Cancer Stages.Digestive diseases and sciences · 2021Article
- Potential alternative treatment approach for pediatric patient with diffusely infiltrative primary rhabdomyosarcoma of the liver.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021Article
- Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports.Einstein (Sao Paulo, Brazil) · 2020Article
- Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization.Journal of clinical medicine · 2019Article
- Emerging trends in modeling human liver diseaseAPL bioengineering · 2019Article
- Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2019Review
- Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.World journal of gastroenterology · 2019Review
- High-Dose-Rate Yttrium-90 (Ophthalmology scienceArticle
- Yttrium-90 Episcleral Plaque Brachytherapy for Choroidal Melanoma.Journal of vitreoretinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) often present at stages where patients have limited treatment options. Use of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres has progressed as data increasingly speak to its utility in patients with both intermediate and late stage disease in these cancers. In anticipation of the pending completion of several prospective randomized controlled multicenter studies exploring the use of Y-90 resin microspheres in primary liver cancers, this article outlines mechanisms involved in SIRT administration and reviews key efficacy and safety data that are currently available in the literature involving use of this therapy in both HCC and ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.